Natera (NTRA) said Tuesday that its Signatera test for patients diagnosed with lung cancer has met coverage requirements for the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.
The company said the coverage is intended for patients with non-small cell lung cancer, specifically patients with stage 1 through stage 3 NSCLC with resectable or unresectable disease.
Natera said the new coverage expands its preexisting Medicare coverage of Signatera for monitoring immunotherapy in adjuvant and metastatic settings.
Price: 154.55, Change: -3.83, Percent Change: -2.42
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。